Skip to main content

Sensitisation and resistant determinants of cancer cells to death receptor related therapies

Objective

In the last decade, an encouraging decline of the death rate from cancer has been observed, as a result of recent advances in prevention, early diagnosis and therapy. Efforts are made towards the generation of "smart" anti-cancer drugs that will target specific molecules depending on the molecular phenotyping of the patient's tumour. TNF-related apoptosis-inducing ligand (TRAIL) is currently a promising anti-tumour agent with proven activity on several cell and animal cancer models. A unique feature of TRAIL is its specificity towards malignant cells while sparing normal cells. At present, pre-clinical studies with recombinant TRAIL are in progress as well as with an anti-TRAIL-R2 monoclonal antibody with no hepatotoxicity.

The aim of the present proposal is to identify components in colon tumours which confer sensitivity or resistance to cell death induced by TRAIL. This project is based on recent findings that oncogenes like RAS or MYC sensitise cells to TRAIL induced apoptosis. For this purpose, human cancer cells a) bearing oncogenic mutations, b) overexpressing oncogenes and c) silencing mutated forms of oncoproteins by RNAi or homologous recombination will be utilised.

In order to identify specific cell death determinants induced by KRAS, BRAF and PIK3CA oncogenes, examination of specific pathways like B-RAF, MEK, PI3K, Rho, BCL-2 will be performed. Studies will be further extended to animal models of tissue specific K-ras induced carcinogenesis. Combined action of TRAIL with other therapeutic molecules will be utilised, in order to succeed optimum effects with minimum concentrations and toxicity. The potential findings of our study will be determined by the present research network and will provide mechanistic basis for a pharmacogenomic approach which could be further therapeutically exploited.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Coordinator

NATIONAL HELLENIC RESEARCH FOUNDATION
Address
48, Vas. Constantinou Avenue
Athens
Greece

Participants (8)

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
Address
Serrano 117
Madrid
DIAGNOSTIC AND THERAPEUTIC CENTRE OF ATHENS HYGEIA S.A.
Greece
Address
Kifissias Av. & 4 Erythrou Stavrou Str.
Maroussi
GENEKOR S.A. CENTRE OF RESEARCH AND ANALYSIS OF GENETIC MATERIAL
Greece
Address
45 Lavriou Avenue
Glyka Nera, Athens
INSTITUT CURIE
France
Address
26 Rue D'ulm'
Paris
INSTITUTE OF MOLECULAR GENETICS ACADEMY OF SCIENCES CZECH REPUBLIC
Czechia
Address
Flemingovo Namesti 22
Prague 6
KAROLINSKA INSTITUTET
Sweden
Address
Nobels Vag. 5
Stockholm
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
Address
123 Old Brompton Road
London
UNIVERSITE DE GENEVE
Switzerland
Address
Rue Du General Dufour, 24
Geneva 4